Paper Details

  1. Home
  2. Paper Details

Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.

Author: AldousJessica, BenitezLydia L, BixbyDale L, BoonstraPhilip, BurkePatrick W, FoleyDaniel H, FoucarCharles E, MariniBernard L, PerissinottiAnthony J, PettitKristen R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A retrospective review of patients with aplastic anemia (AA) treated with immunosuppressive therapy (IST) showed that dose-attenuated IST was feasible and safe in older patients (>60) with concerns about tolerability. Younger patients receiving IST, especially in combination with eltrombopag, showed favorable outcomes.
Paper Details　
Original Abstract of the Article :
Aplastic anemia (AA) is a rare bone marrow failure disorder that is treated with either allogeneic stem cell transplant or immunosuppressive therapy (IST) consisting of antithymocyte globulin (ATG), cyclosporine (CSA), and eltrombopag. While outcomes are favorable in younger patients, older patients...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/ejh.14131

データ提供：米国国立医学図書館（NLM）

Immunosuppressive Therapy: Navigating the Desert of Aplastic Anemia

Aplastic anemia (AA) is a rare bone marrow failure disorder that can be life-threatening. Treatment options for AA include immunosuppressive therapy (IST) and allogeneic stem cell transplant. While IST is a viable option for younger patients, older patients with multiple comorbidities may experience challenges with tolerability. This research investigates the efficacy and safety of dose-attenuated IST in older patients with AA. They conducted a retrospective review of patients with AA treated with IST, comparing outcomes between full and attenuated dose cohorts. Their analysis revealed that dose-attenuated IST was well-tolerated and resulted in similar response rates and overall survival compared to the full dose cohort.

Dose-Attenuated IST: A Tailor-Made Approach for Older Patients

This research emphasizes the importance of considering individual patient needs when designing treatment strategies for AA. By adjusting the dosage of IST based on age and comorbidities, clinicians can potentially improve tolerability and optimize outcomes for older patients.

Immunosuppressive Therapy: A Path Towards Bone Marrow Recovery

This research offers a valuable insight into the management of AA, highlighting the potential of dose-attenuated IST as a safe and effective option for older patients. It underscores the importance of personalized care in navigating this complex disease.

Dr.Camel's Conclusion

This research is a testament to the adaptable nature of medical treatments. It's like finding a hidden oasis of tailored care in the vast desert of AA treatment. By adjusting the dosage of IST to meet the unique needs of each patient, we can help them navigate their journey towards recovery.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

37929654

DOI: Digital Object Identifier

10.1111/ejh.14131

Related Literature

Article Analysis
・Effects of eltrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.